COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #18 of 231
4/24 Early treatment study
Ashraf et al., medRxiv doi:10.1101/2020.04.20.20072421.t (Preprint)
COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Source   PDF   Share   Tweet
Small limited trial with 100 patients concluding that HCQ improved clinical outcome, OR 0.016 [0.002-0.11] in regression analysis.

Ashraf et al., 4/24/2020, retrospective, database analysis, Iran, Middle East, preprint, median age 58.0, 16 authors, dosage 200mg bid daily, 400mg qd was used when combined with Lopinavir-Ritonavir.
risk of death, 67.5% lower, RR 0.32, p = 0.15, treatment 10 of 77 (13.0%), control 2 of 5 (40.0%).
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit